MTM-H-001 for adults with relapsed or refractory B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new injection, MTM-H-001, in adults whose B-cell lymphoma has returned or not responded after at least two prior treatments. The goal is to see if it can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of B-cell lymphoma that has come back or not improved after at least two standard treatments.
- Your major organs, like bone marrow, liver, kidneys, and heart, are working well enough (specific lab tests will be done).
- You are able to take care of yourself (ECOG score of 0-2) and expected to live more than 3 months.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
This study tests a new injection called MTM-H-001 to treat autoimmune diseases where the body's B cells attack itself (like rheumatoid arthritis or lupus). The trial aims to see if this treatment is safe and effective for adults.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
This early-phase trial tests MT-601 (an experimental treatment) in adults whose lymphoma has come back or didn’t respond to standard treatments. The study mainly checks safety, and it also looks for early signs that the treatment can shrink tumors.
This early-stage trial tests a new cell therapy called GI001 for patients with B-cell lymphomas or leukemias that have come back or stopped responding to standard treatments. The therapy is designed to help your immune system recognize and fight cancer cells.
Hear when a new Transformed Follicular Lymphoma (TFL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.